Redx Pharma Plc (LON:REDX)

Redx Pharma Plc (LON:REDX)

Share Price
5.35 p
0 (0.00 %)
Market Cap
£6.77 m
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc

Redx Pharma was formed in 2010 and is an established drug discovery and development company based at Alderley Park. The Group’s work has been endorsed by partnerships with global pharmaceutical companies, and focuses on the development of proprietary, small molecule therapeutics to address areas of high unmet medical need in cancer and fibrosis.

Market: AIM:REDX
52-week High/Low: 11.45p / 4.75p
Sector: Pharma & Biotech
Market Cap: £6.77 m
col 3
col 4
col 5
col 6

Redx Pharma Plc RNS Announcements

Date Epic Announcement
24/04/2018 REDX Redx Appoints Senior AstraZeneca Executive as CEO
13/04/2018 REDX Holding(s) in Company
12/04/2018 REDX Holding(s) in Company
29/03/2018 REDX RXC004 Clinical Trial Update
22/03/2018 REDX Redx and Deinove sign option and licence agreement
15/03/2018 REDX Poster Presentation at AACR Annual Meeting
06/03/2018 REDX Result of AGM
12/02/2018 REDX Posting of Annual Accounts & AGM notice
06/02/2018 REDX First Patient Dosed in Phase 1/2a Trial of RXC004
22/01/2018 REDX Appointment of Chief Medical Officer
28/12/2017 REDX Holding(s) in Company
27/12/2017 REDX Share Purchase by Directors
22/12/2017 REDX Grant of Options
20/12/2017 REDX Final Results for the Year Ended 30 September 2017
14/12/2017 REDX Holding(s) in Company
08/12/2017 REDX Holding(s) in Company
14/11/2017 REDX Director/PDMR Shareholding
13/11/2017 REDX Hardman Research: Streamlined and clean
06/11/2017 REDX Redx updates strategy and resumes shares trading
03/11/2017 REDX Exit from Administration
27/10/2017 REDX Update on Application to the High Court
13/10/2017 REDX Update on Court Process
31/08/2017 REDX Redx to present new scientific data at ESMO 2017
24/08/2017 REDX Distribution to Unsecured Creditors
14/08/2017 REDX Directorate Change
10/08/2017 REDX Publication of Joint Administrators' Proposals
31/07/2017 REDX Disposal of BTK inhibitor drug development program
23/06/2017 REDX MHRA approval of Clinical Trial Application
22/06/2017 REDX Update on Suspension of Trading
24/05/2017 REDX Statement re. Suspension

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use